dacarbazine,doxorubicin,brentuximab vedotin,vinblastine,bleomycin,vincristine
seagen
[]
the big debate, people s vote:
3. should a+avd replace pet driven strategies for advanced chl? ansell vs borchmann. no!
(the winner is brecadd)
#17icml 
Oncologist at Uppsala university hospital. Chair of the Swedish lymphoma group (SLG) and the Swedish Hodgkin lymphoma group.